Turkish IBD Organization’s Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic
Main Article Content
Abstract
The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2, has resulted in high mortality and morbidity
worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial
number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating
evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive
treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness
and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations
for the management of IBD in the context of the COVID-19 pandemic.
worldwide and is still a growing problem. Inflammatory bowel disease (IBD) is a chronic inflammatory disease for which a substantial
number of patients are treated with immunosuppressive medications, either occasionally or long-term. Despite the accumulating
evidence, there is still a lack of knowledge about the impact of COVID-19 on IBD patients, especially those who are under immunosuppressive
treatment. Moreover, following the emergence of several COVID vaccines, there are concerns regarding vaccine effectiveness
and possible side effects in such patients. In this context, we tried to briefly summarize the accumulating evidence and recommendations
for the management of IBD in the context of the COVID-19 pandemic.